The role of posttranslational modifications of α-synuclein and LRRK2 in Parkinson's disease: Potential contributions of environmental factors

被引:28
|
作者
Pajarillo, Edward [1 ]
Rizor, Asha [1 ]
Lee, Jayden [2 ]
Aschner, Michael [3 ]
Lee, Eunsook [1 ]
机构
[1] Florida A&M Univ, Coll Pharm, Dept Pharmaceut Sci, Tallahassee, FL 32301 USA
[2] Boston Univ, Dept Speech Language & Hearing Sci, Boston, MA 02215 USA
[3] Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA
基金
美国国家卫生研究院;
关键词
alpha-Synuclein; LRRK2; Parkinson's disease; Manganese; Posttranslational modifications; REPEAT KINASE 2; N-TERMINAL ACETYLATION; IN-VITRO; DOPAMINERGIC NEURODEGENERATION; MITOCHONDRIAL DYSFUNCTION; DOMINANT PARKINSONISM; TYROSINE NITRATION; OXIDATIVE STRESS; SUBSTANTIA-NIGRA; 14-3-3; BINDING;
D O I
10.1016/j.bbadis.2018.11.017
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Parkinson's disease (PD) is the second most common neurodegenerative disease after Alzheimer's disease (AD), and the most prevalent movement disorder. PD is characterized by dopaminergic neurodegeneration in the substantia nigra, but its etiology has yet to be established. Among several genetic variants contributing to PD pathogenesis, alpha-synuclein and leucine-rich repeat kinase (LRRK2) are widely associated with neuropathological phenotypes in familial and sporadic PD. alpha-Synuclein and LRRK2 found in Lewy bodies, a pathogenic hallmark of PD, are often posttranslationally modified. As posttranslational modifications (PTMs) are key processes in regulating the stability, localization, and function of proteins, PTMs have emerged as important modulators of alpha-synuclein and LRRK2 pathology. Aberrant PTMs altering phosphorylation, ubiquitination, nitration and truncation of these proteins promote PD pathogenesis, while other PTMs such as sumoylation may be protective. Although the causes of many aberrant PTMs are unknown, environmental risk factors may contribute to their aberrancy. Environmental toxicants such as rotenone and paraquat have been shown to interact with these proteins and promote their abnormal PTMs. Notably, manganese (Mn) exposure leads to a PD-like neurological disorder referred to as manganism-and induces pathogenic PTMs of alpha-synuclein and LRRK2. In this review, we highlight the role of PTMs of alpha-synuclein and LRRK2 in PD pathogenesis and discuss the impact of environmental risk factors on their aberrancy.
引用
收藏
页码:1992 / 2000
页数:9
相关论文
共 50 条
  • [31] Exploring the focal role of LRRK2 kinase in Parkinson's disease
    Kumar, Sachin
    Behl, Tapan
    Sehgal, Aayush
    Chigurupati, Sridevi
    Singh, Sukhbir
    Mani, Vasudevan
    Aldubayan, Maha
    Alhowail, Ahmed
    Kaur, Satvinder
    Bhatia, Saurabh
    Al-Harrasi, Ahmed
    Subramaniyan, Vetriselvan
    Fuloria, Shivkanya
    Fuloria, Neeraj Kumar
    Sekar, Mahendran
    Daim, Mohamed M. Abdel
    ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH, 2022, 29 (22) : 32368 - 32382
  • [32] Role of LRRK2 kinase dysfunction in Parkinson disease
    Kumar, Azad
    Cookson, Mark R.
    EXPERT REVIEWS IN MOLECULAR MEDICINE, 2011, 13 : e20
  • [33] THE COMPLEX RELATIONSHIPS BETWEEN MICROGLIA, ALPHA-SYNUCLEIN, AND LRRK2 IN PARKINSON'S DISEASE
    Schapansky, J.
    Nardozzi, J. D.
    Lavoie, M. J.
    NEUROSCIENCE, 2015, 302 : 74 - 88
  • [34] LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease
    Alegre-Abarrategui, J.
    Ansorge, O.
    Esiri, M.
    Wade-Martins, R.
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2008, 34 (03) : 272 - 283
  • [35] LRRK2 inhibitors and their potential in the treatment of Parkinson's disease: current perspectives
    Atashrazm, Farzaneh
    Dzamko, Nicolas
    CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2016, 8 : 177 - 189
  • [36] LRRK2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications
    Qing, H.
    Wong, W.
    McGeer, E.
    McGeer, P.
    PARKINSONISM & RELATED DISORDERS, 2009, 15 : S197 - S197
  • [37] Hypercholinergic activity in LRRK2 Parkinson's disease
    Bohnen, Nicolaas I.
    Albin, Roger L.
    LANCET NEUROLOGY, 2018, 17 (04): : 290 - 291
  • [38] Genetics of Parkinson's disease: LRRK2 on the rise
    Brice, A
    BRAIN, 2005, 128 : 2760 - 2762
  • [39] Metabolomic analysis in LRRK2 Parkinson's disease
    Johansen, K. K.
    Matson, W.
    Beal, F.
    Aasly, J. O.
    Bogdanov, M.
    MOVEMENT DISORDERS, 2007, 22 : S187 - S187
  • [40] Inhibitors of LRRK2 as Treatment for Parkinson's Disease
    Abdel-Magid, Ahmed F.
    ACS MEDICINAL CHEMISTRY LETTERS, 2012, 3 (09): : 701 - 702